No Data
Express News | 14 listed companies' stocks were repurchased, with Zhejiang JIULI Hi-tech Metals having the highest repurchase amount.
Tianjin Lisheng Pharmaceutical (002393.SZ): has repurchased a total of 2.37% of its shares.
On January 7, Gelonghui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) announced that as of January 7, 2025, the company repurchased shares through a dedicated securities account for Share Buyback via centralized bidding, with a total of 6,104,940 shares repurchased, accounting for 2.37% of the company's current total share capital. The highest Fill Price was 18.50 yuan per share, the lowest Fill Price was 17.28 yuan per share, and the total transaction amount was 0.109 billion yuan (excluding transaction fees).
Overview of the lifting of restrictions on A-shares | December 30
According to Zhichun Financial APP, on December 30, a total of 37 listed companies had their restricted shares unlocked, with a total market value of approximately 12.254 billion yuan. Today's specific situation of the restricted shares unlocked is as follows: Stock Abbreviation Stock Code Restricted Stock Type Number of Stocks Unlocked Henan Yuneng Holdings 001896 Placement of A-shares for original shareholders 0.205 billion Datang Telecom Technology 600198 Placement of A-shares for original shareholders 0.428 billion China National Software & Service 600536 Stock-based Incentive restricted circulation 0.7513 million Xiamen Tungsten 600549 Stock-based Incentive restricted circulation 3.6369 million Yueyang Forest & Paper 600963 Stock-based Incentive restricted circulation 0.27 million
Tianjin Development Subsidiary to Repurchase Shares, Grant Shares Under Share Award Scheme
TIANJIN DEV (00882.HK) subsidiary Tianjin Lisheng Pharmaceutical suggests a buyback with a funding limit of 0.153 billion yuan.
TIANJIN DEV (00882.HK) announced that its subsidiary Tianjin Lisheng Pharmaceutical (002393.SZ) proposes to repurchase shares through centralized bidding trading starting immediately for a total amount of no less than 76.5 million yuan and not exceeding 0.153 billion yuan within twelve months.
Tianjin Lisheng Pharmaceutical (002393.SZ): Plans to launch the 2024 restricted stock incentive plan.
On December 20, Gelonghui reported that Tianjin Lisheng Pharmaceutical (002393.SZ) announced its 2024 Stock-based Incentive Plan, which proposes to grant no more than 7,210,000 shares of restricted stocks to the incentive objects, accounting for approximately 2.80% of the company’s total share capital of 257,942,988 shares. Among these, 5,770,000 shares of restricted stocks will be granted initially, accounting for 80.03% of the total number of restricted stocks; about 1,440,000 shares of restricted stocks will be reserved, accounting for 19.97% of the total number of restricted stocks. After the implementation of this incentive plan, the company's entire effective equity incentive plan will be.
No Data
